Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Entries are now open for the Global Generics & Biosimilars Awards 2019, which will this year be presented on Tuesday 5 November at the Frankfurt Marriott Hotel in Frankfurt, Germany.
Now in their sixth year, the Awards – which are free to enter and attend – have added two new categories to the roster for 2019: Value Added Medicine Of The Year and Legal Strategy Of The Year.
Entries in the Value Added Medicine Of The Year category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.
Meanwhile, the Legal Strategy Of The Year category allows generics, biosimilars and value-added medicines firms as well as their partnering law firms to highlight outstanding results from their legal strategy. This could include notable litigation results allowing a competitive advantage or early launch; inventive ways of getting around or invalidating intellectual property; or ways in which legal strategies from different global jurisdictions have been used as a template elsewhere, showing the benefits of a co-ordinated international legal strategy.
Entries Now Open Until August
Companies and individuals involved in the generics, biosimilars and value added medicines industries can submit by 9 August 2019 their entries for all 14 awards, which will be judged by expert panels.
Awards available for entry include the Company of the Year Award as well as three local Company of the Year Awards for the Americas, EMEA and Asia-Pacific regions.
Other Awards include the Business Development of the Year Award – sponsored by West Pharma – as well as the Acquisition of the Year, API Supplier of the Year, Biosimilar Initiative of the Year, Regulatory Achievement of the Year and Industry Partner of the Year Awards.
Company leadership will be recognized by the Leader of the Year Award, while International Health Partners (IHP) will once again sponsor the Award for Corporate Social Responsibility (CSR) Initiative of the Year.
For more information an to enter the awards, please follow this link.
Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Biomedtracker: follow the drug development process
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, you stay on top of breaking events, what’s in the drugs pipeline, upcoming milestones, clinical trial results and their impact on the markets you care about
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.